12-(5-bromopentyl)-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]-indole | 866595-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 12-(5-bromopentyl)-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]-indole
• 英文别名: 12-(5-bromopentyl)-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]indole；12-(5-Bromopentyl)-5,6,7,12-tetrahydro-benzo [6,7]cyclohepta[1,2-b]indole；18-(5-bromopentyl)-18-azatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2,4,6,12,14,16-heptaene
• CAS: 866595-58-6
• 化学式: C₂₂H₂₄BrN
• 分子量: 382.343
• InChiKey: IJXFAPOVPGBIRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  甲基丁胺 、 12-(5-bromopentyl)-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]-indole 在 四丁基碘化铵 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 7.0h， 以80.8%的产率得到12-[5-(N-butyl-methyl-amino)pentyl]-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]indole
  参考文献：
  名称：

  [EN] NOVEL N-SUBSTITUTED DIHYDROBENZOTHIEPINO, DIHYDROBENZOXEPINO AND TETRAHYDRO BENZOCYCLOHEPTA INDOLES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
  [FR] NOUVEAUX DIHYDROBENZOTHIEPINO, DIHYDROBENZOXEPINO ET TETRAHYDRO BENZOCYCLOHEPTA INDOLES N-SUBSTITUES UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DES OESTROGENES

  摘要：

  这项发明提供了一类新型的Formula (I)的N-取代二氢苯并噻吩、二氢苯并氧吩和四氢苯并环庚哌啉以及它们的药用盐，以及合成这些化合物的方法。该发明还包括用于治疗雌激素相关疾病或紊乱的这些化合物的药用组合物和使用方法。

  公开号：

  WO2005094833A1
• 作为产物：
  描述：

  1,5-二溴戊烷 、 5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]indole 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.75h， 以77.4%的产率得到12-(5-bromopentyl)-5,6,7,12-tetrahydro-benzo[6,7]cyclohepta[1,2-b]-indole
  参考文献：
  名称：

  [EN] NOVEL N-SUBSTITUTED DIHYDROBENZOTHIEPINO, DIHYDROBENZOXEPINO AND TETRAHYDRO BENZOCYCLOHEPTA INDOLES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
  [FR] NOUVEAUX DIHYDROBENZOTHIEPINO, DIHYDROBENZOXEPINO ET TETRAHYDRO BENZOCYCLOHEPTA INDOLES N-SUBSTITUES UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DES OESTROGENES

  摘要：

  这项发明提供了一类新型的Formula (I)的N-取代二氢苯并噻吩、二氢苯并氧吩和四氢苯并环庚哌啉以及它们的药用盐，以及合成这些化合物的方法。该发明还包括用于治疗雌激素相关疾病或紊乱的这些化合物的药用组合物和使用方法。

  公开号：

  WO2005094833A1

文献信息

• Novel-N substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators
  申请人：Hajela Kanchan

  公开号：US20050282863A1

  公开（公告）日：2005-12-22

  The invention provides a novel class of N-substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles and their pharmaceutically acceptable salts, and methods for of synthesizing these compounds. The invention further comprises pharmaceutical compositions and methods of use for these compounds for the treatment of estrogen related diseases or disorders.

  本发明提供了一种新型的N-取代的二氢苯并硫吩、二氢苯并氧吩和四氢苯并环庚基吲哚及其药学上可接受的盐，并提供了合成这些化合物的方法。本发明还包括这些化合物的药物组成物和用于治疗雌激素相关疾病或疾病的方法。
• Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents
  作者：Uma Sharan Singh、Ravi Shankar、Avinash Kumar、Ritu Trivedi、Naibedya Chattopadhyay、Nishi Shakya、Shraddha Palne、Suman Gupta、K. Hajela

  DOI：10.1016/j.bmc.2008.08.024

  日期：2008.9

  A series of indole conjugated bisphosphonate derivatives have been synthesized and evaluated for their in vitro anti-bone resorptive activity using bone marrow osteoclast culture. Two bisphosphonates 23 and 24 significantly inhibited osteoclastogenesis, 23 showed inhibition at 10 and 100 pM which was lower than the concentration of standard drug alendronate, and 24 inhibited osteoclastogenesis at 100 nM which was comparable to alendronate. Two other compounds 13 and 14 also showed inhibition comparable to alendronate, but were cytotoxic in the osteoblast cells. The two active bisphosphonates 23 and 24 induced significant osteoclast apoptosis at concentrations 100 nM for compound 24 and at 10 pM for compound 23 compared to alendronate. In vivo effect of active bisphosphonates 23 and 24 resulted in osteoclastogenesis of bone marrow cells (BMCs) to almost 40-50% (23 showing 8.4% decrease and 24 showing 9.0%) compared to 16.5% of the ovariectomized group. Further, screening of anti-leishmanial activity, four compounds 24-25 and 27-28 showed more than 80% inhibition against both the promastigote and amastigote stages of the Leishmania parasite. (C) 2008 Elsevier Ltd. All rights reserved.